Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies

BACKGROUND: HER2-positive metastatic breast cancer (MBC) relapsing after trastuzumab-based therapy may require continued HER2 receptor inhibition to control the disease and preserve the patients' quality-of-life. Efficacy and safety of lapatinib monotherapy was evaluated in Japanese breast canc...

Descripción completa

Detalles Bibliográficos
Autores principales: Toi, M, Iwata, H, Fujiwara, Y, Ito, Y, Nakamura, S, Tokuda, Y, Taguchi, T, Rai, Y, Aogi, K, Arai, T, Watanabe, J, Wakamatsu, T, Katsura, K, Ellis, C E, Gagnon, R C, Allen, K E, Sasaki, Y, Takashima, S
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778543/
https://www.ncbi.nlm.nih.gov/pubmed/19844234
http://dx.doi.org/10.1038/sj.bjc.6605343

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2778543/
https://www.ncbi.nlm.nih.gov/pubmed/19844234
http://dx.doi.org/10.1038/sj.bjc.6605343

Ejemplares similares